An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02581631 |
|
Recruitment Status : Unknown
Verified March 2020 by Bristol-Myers Squibb.
Recruitment status was: Active, not recruiting
First Posted : October 21, 2015
Last Update Posted : March 24, 2020
|
Sponsor:
Bristol-Myers Squibb
Collaborator:
Seagen Inc.
Information provided by (Responsible Party):
Bristol-Myers Squibb
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-Hodgkin's Disease | Biological: Nivolumab Drug: Brentuximab Vedotin | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 146 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436) |
| Actual Study Start Date : | December 18, 2015 |
| Actual Primary Completion Date : | January 16, 2020 |
| Estimated Study Completion Date : | August 30, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Nivolumab+Brentuximab Vedotin
Nivolumab+Brentuximab Vedotin dose as specified
|
Biological: Nivolumab Drug: Brentuximab Vedotin |
Primary Outcome Measures :
- Safety of combination of nivolumab and brentuximab vedotin based on incidence of deaths, adverse events (AE), serious adverse events (SAE), AE leading to discontinuation, AE leading to dose delay, drug-related adverse events [ Time Frame: Approximately 2.5 years ]
- Tolerability of combination of nivolumab and brentuximab vedotin based on incidence of deaths, AE, SAE, adverse events leading to discontinuation, adverse events leading to dose delay, drug-related adverse events [ Time Frame: Approximately 2.5 years ]
- Overall Response Rate (ORR) [ Time Frame: 8 months after the last patient receives their first dose ]Overall Response Rate: Defined as the number of subjects with a best overall response (BOR) of confirmed complete remission (CR) or Partial response (PR) divided by the number of treated subjects
Secondary Outcome Measures :
- Overall duration of response (DOR) [ Time Frame: 8 months after the last patient receives their first dose ]Duration of response: DOR will be calculated from the date of initial documentation of a response (CR, or PR) to the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death
- Complete response rate (CRR) [ Time Frame: 8 months after the last patient receives their first dose ]Complete response rate: Defined as the number of subjects with a BOR of CR divided by the number of treated subjects
- Duration of complete response [ Time Frame: 8 months after the last patient receives their first dose ]The duration of CR will only be evaluated in subjects with BOR of CR and is defined as the time from first documentation of CR to the date of initial documented progression or death due to any cause, whichever occurs first
- Progression-Free Survival (PFS) [ Time Frame: 8 months after the last patient receives their first dose ]PFS is defined as the time from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever comes first
- Overall Survival (OS) [ Time Frame: 1 year after the first patient receives their first dose ]OS is defined as the time from the date of first dose of study drug until the date of death
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Relapsed/refractory diffuse large B cell lymphoma (DLBCL), relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS), relapsed/refractory primary mediastinal B lymphoma (PMBL), and relapsed/refractory mediastinal gray zone lymphoma (MGZL)
- Expression of CD30
- Subjects must be 18 years or older (≥ 15 years for PMBL)
Exclusion Criteria:
- Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy
- Active, known, or suspected autoimmune disease
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02581631
Locations
Show 27 study locations
Sponsors and Collaborators
Bristol-Myers Squibb
Seagen Inc.
Investigators
| Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Bristol-Myers Squibb |
| ClinicalTrials.gov Identifier: | NCT02581631 |
| Other Study ID Numbers: |
CA209-436 2015-003286-28 ( EudraCT Number ) |
| First Posted: | October 21, 2015 Key Record Dates |
| Last Update Posted: | March 24, 2020 |
| Last Verified: | March 2020 |
Additional relevant MeSH terms:
|
Lymphoma, Non-Hodgkin Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders |
Immune System Diseases Nivolumab Brentuximab Vedotin Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |